Drug Information

Drug (ID: DG01784) and It's Reported Resistant Information

• Name: Urethane
• Synonyms: Urethane; ETHYL CARBAMATE; 51-79-6; Urethan; Ethylurethane; Carbamic acid, ethyl ester; Carbamic acid ethyl ester; Leucethane; Pracarbamine; Ethyl urethane; Ethylcarbamate; Pracarbamin; Ethyl urethan; O-Ethylurethane; U-Compound; Aethylcarbamat; Aethylurethan; Ethylurethan; Leucothane; Estane 5703; Uretan; Uretano [DCIT]; Uretan etylowy; NSC 746; Aethylurethan [German]; Aethylcarbamat [German]; ethyl aminoformate; O-Ethyl urethane; Carbamidsaeure-aethylester; RCRA waste number U238; Ethyl ester of carbamic acid; Ethylester kyseliny karbaminove; X 41; MFCD00007966; UNII-3IN71E75Z5; A 11032; NH2COOC2H5; NSC746; CHEBI:17967; NSC-746; Urethane + ethanol (combination); 3IN71E75Z5; Aethylurethan (german); NCGC00095041-01; Aethylcarbamat (german); DSSTox_CID_1427; Urethanum [INN-Latin]; Uretan etylowy [Polish]; DSSTox_RID_76156; DSSTox_GSID_21427; Ethyl carbamate;Carbamic acid ethyl ester;Ethylurethane; Uretano; Urethanum; Carbamate, Ethyl; Carbamidsaeure-aethylester [German]; o-Ethyl carbamate; Ethyl Carbamate (Urethane); CAS-51-79-6; Urethane [INN:BAN:DCF]; CCRIS 619; Ethylester kyseliny karbaminove [Czech]; HSDB 2555; Urethane [INN:DCF]; SR-05000001854; EINECS 200-123-1; RCRA waste no. U238; AI3-00553; Urethane, INN; Spectrum_001685; Urethane, >=99%; Spectrum2_000909; Spectrum3_000965; Spectrum4_001082; Spectrum5_001651; WLN: ZVO2; BSPBio_002569; KBioGR_001464; KBioSS_002165; Urethane, analytical standard; BIDD:ER0508; DivK1c_000060; SPECTRUM1503304; SPBio_000758; CHEMBL462547; DTXSID9021427; HMS500C22; KBio1_000060; KBio2_002165; KBio2_004733; KBio2_007301; KBio3_001789; NINDS_000060; Urethane, >=99.0% (GC); HMS1922A10; HMS2093C21; HMS3885F08; Pharmakon1600-01503304; ZINC901020; HY-B1207; Tox21_111398; Tox21_201761; Tox21_300494; CCG-39905; NSC758452; s4544; STL257390; AKOS000118772; Tox21_111398_1; CS-4731; DB04827; MCULE-1776877276; NSC-758452; IDI1_000060; NCGC00095041-02; NCGC00095041-03; NCGC00095041-04; NCGC00095041-05; NCGC00095041-06; NCGC00095041-08; NCGC00254522-01; NCGC00259310-01; SBI-0051812.P002; SBI-0051812.P003; DB-052027; AM20100253; FT-0626365; FT-0675741; C01537; F21294; AB00052344_04; Q422884; SR-05000001854-1; SR-05000001854-2; BRD-K24297741-001-01-1; Carbamic acid ethyl ester;Ethyl carbamate;Ethylurethane; Z33546369; F0001-1333
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  Lung cancer [ICD-11: 2C25]; [1]
• Target: .; NOUNIPROTAC; [2]
• Formula: 2
• IsoSMILES: CCOC(=O)N
• InChI: InChI=1S/C3H7NO2/c1-2-6-3(4)5/h2H2,1H3,(H2,4,5)
• InChIKey: JOYRKODLDBILNP-UHFFFAOYSA-N
• PubChem CID: 5641
• VARIDT ID: DR1663
• DrugBank ID: DB04827

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

  RTDM: Regulation by the Disease Microenvironment

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Lung cancer [ICD-11: 2C25]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Growth arrest specific 5 (GAS5) [2]

• Molecule Alteration: Down-regulation; Expression
• Resistant Disease: Lung adenocarcinoma [ICD-11: 2C25.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: 16HBE cells; Lung; Homo sapiens (Human); CVCL_0112
• In Vivo Model: BALB/c nude mice model; Mus musculus
• Experiment for Molecule Alteration: Overexpression assay
• Experiment for Drug Resistance: EdU assay
• Mechanism Description: Low Long Noncoding RNA Growth Arrest-Specific Transcript 5 Expression in the Exosomes of Lung Cancer Cells Promotes Tumor Angiogenesis.

Regulation by the Disease Microenvironment (RTDM)

Key Molecule: Growth arrest specific 5 (GAS5) [1]

• Molecule Alteration: Down-regulation; Interaction
• Resistant Disease: Lung adenocarcinoma [ICD-11: 2C25.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: 16HBE cells; Lung; Homo sapiens (Human); CVCL_0112
• In Vivo Model: BALB/c nude mice model; Mus musculus
• Experiment for Molecule Alteration: Overexpression assay
• Experiment for Drug Resistance: EdU assay
• Mechanism Description: Low Long Noncoding RNA Growth Arrest-Specific Transcript 5 Expression in the Exosomes of Lung Cancer Cells Promotes Tumor Angiogenesis.

References

• Ref 1: lncRNA GAS5 restrains CCl(4)-induced hepatic fibrosis by targeting miR-23a through the PTEN/PI3K/Akt signaling pathwayAm J Physiol Gastrointest Liver Physiol. 2019 Apr 1;316(4):G539-G550. doi: 10.1152/ajpgi.00249.2018. Epub 2019 Feb 8.
• Ref 2: Low Long Noncoding RNA Growth Arrest-Specific Transcript 5 Expression in the Exosomes of Lung Cancer Cells Promotes Tumor AngiogenesisJ Oncol. 2019 May 2;2019:2476175. doi: 10.1155/2019/2476175. eCollection 2019.